LintonPharm announces authorization from China health authority (NMPA) to proceed with a phase 1/2 trial evaluating catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that China’s health authority, …
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that China’s health authority, …